WHO recommends monoclonal antibodies for ‘high risk’ COVID patients
SWITZERLAND: The World Health Organization (WHO) has recommended treatment with the combination of two monoclonal antibodies (Casirivimab and imdevimab) for two groups of high-risk patients with Covid-19 in its latest living…
Read More...
Read More...
